Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

BML-190Also known as indomethacin morpholinylamide

Indomethacin derivative, a CB2 ligand (Ki 435 nM) described as an inverse agonist; a tool for measuring the receptor's constitutive activity.

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₃H₂₃ClN₂O₄

CAS 2854-32-2

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
426.90 g/mol

Updated on

In plain terms

BML-190 derives from indomethacin, a non-steroidal anti-inflammatory drug, modified on a single chemical function. It binds to the CB2 receptor and, in cultured cells, it reduces the spontaneous activity of this receptor instead of activating it. It is a laboratory tool, with no medical use and no consumer product.

Receptors and activity

Target network

CB2Inverse agonistKi = 435 nM · humanaffinity for the recombinant human CB2 receptor (Gallant et al. 1996, cited by Zhang et al. 2010); inverse agonism on cAMP and inositol phosphates (New and Wong 2003)
  • Blocks or inhibits
  • Binds or modulates

The lower the cited value, the closer the target sits to BML-190: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of BML-190.

Brain, side view
Body, front view
Blood

CB2CB2 found in 5 regions of the body

  1. SpleendenseHighly abundant in the spleen1
  2. Immune cellspresentMainly B cells and natural killer cells1
  3. SkinpresentKeratinocytes, mast cells and nerve fibres2
  4. GutpresentImmune cells of the colonic mucosa3
  5. BonepresentPresent on osteoclasts4

Cited values

  1. CB2Inverse agonistKi = 435 nM · human39 out of 100

    Zhang et al., Eur J Pharm Sci 2010: in vitro metabolism of indomethacin morpholinylamide on rat liver microsomes (cites Gallant et al. 1996, Bioorg Med Chem Lett, not indexed in PubMed, for the Ki values) (new tab) · affinity for the recombinant human CB2 receptor (Gallant et al. 1996, cited by Zhang et al. 2010); inverse agonism on cAMP and inositol phosphates (New and Wong 2003)

  2. CB1Binding (function not established)no measured value cited

    Ki greater than 20 000 nM at recombinant human CB1 (Gallant et al. 1996, cited by Zhang et al. 2010): no measurable affinity

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

BML-190 (indomethacin morpholinylamide) is a derivative of indomethacin, a non-steroidal anti-inflammatory drug, in which the carboxylic acid function is replaced by a morpholine amide. Zhang et al. (2010) classify it among the aminoalkylindoles and recall that it was described in 1996 by Gallant et al. as a selective CB2 ligand, with a Ki of 435 nM at human CB2 and above 20,000 nM at CB1; it was then presented as a CB2 agonist. The nature of the interaction was clarified in 2003 by New and Wong: in HEK-293 cells stably expressing human CB2, the compound potentiates forskolin-induced cAMP accumulation and lowers basal inositol phosphate production when the receptor is coupled to a chimeric G protein, the opposite of an agonist effect. It therefore acts as an inverse agonist through two families of signalling pathways, Gi/o and Gq, like AM251 in the same work. This property only shows in a system where the receptor has measurable constitutive activity; it makes BML-190 a tool for detecting it. Its metabolism was characterised in vitro in rat liver microsomes, where at least fifteen products were identified by HPLC-MS/MS (Zhang et al. 2010). No in vivo, pharmacokinetic or human data were found in the sources consulted.

History

Source
Entirely synthetic compound derived from an existing drug, indomethacin. It is used as a pharmacology reagent; no clinical development was found in the sources consulted.

Origin

Research tool

No known biosynthetic pathway: a synthetic molecule. It derives from indomethacin, with the carboxylic acid function replaced by a morpholine amide; the methoxylated and methylated indole ring, acylated on its nitrogen by a 4-chlorobenzoyl group, is retained (chemical name and formula checked on PubChem, CID 2415).

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

BML-190 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
BML-190 (indomethacin morpholinylamide)
IUPAC name
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-1-morpholin-4-ylethanone
Other names
BML190 · Indomethacin morpholinylamide · IMMA

Identifiers

Formula
C₂₃H₂₃ClN₂O₄
CAS
2854-32-2
PubChem CID
2415(new tab)
InChIKey
BJSDNVVWJYDOLK-UHFFFAOYSA-N
SMILES
CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)N4CCOCC4

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.